Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive)

Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.

Also Known As:

Networked: 970 relevant articles (21 outcomes, 63 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Rhabdomyosarcoma
3.	Infertility (Sterility)
4.	Infections
5.	Fibrosis (Cirrhosis)

Experts

1.	Richardson, Paul G: 24 articles (11/2022 - 06/2007)
2.	Corbacioglu, Selim: 13 articles (06/2022 - 04/2012)
3.	Kernan, Nancy A: 13 articles (01/2022 - 02/2010)
4.	Iacobelli, Massimo: 13 articles (01/2020 - 01/2006)
5.	Antin, Joseph H: 12 articles (11/2022 - 02/2010)
6.	Yang, Li: 12 articles (04/2022 - 12/2010)
7.	Carreras, Enric: 12 articles (12/2021 - 02/2010)
8.	McDonald, George B: 11 articles (01/2019 - 02/2002)
9.	Ho, Vincent T: 10 articles (11/2022 - 06/2007)
10.	Richardson, Paul: 10 articles (01/2020 - 11/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hepatic Veno-Occlusive Disease:

1.	defibrotideIBA 08/01/2012 - "Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease." 05/01/2023 - "Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial." 01/01/2023 - "Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study." 06/01/2022 - "A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome." 12/01/2019 - "Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)."
2.	Heparin (Liquaemin)FDA LinkGeneric 01/01/2022 - "Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant." 02/01/1996 - "Low dose intravenous heparin was used as prophylaxis for hepatic veno-occlusive disease. " 06/01/1992 - "Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial." 02/01/2007 - "[Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation]." 03/10/2001 - "Continuous intravenous drip of heparin in low dose with Lipo protaglandin E1 was given to prevent hepatic veno-occlusive disease (VOD). "
3.	MonocrotalineIBA 01/01/2023 - "Although many experiments have been carried out to explain the pathogenesis of Monocrotaline-induced hepatic sinusoidal obstruction syndrome and to develop treatments for it, no studies have examined the role of Long non-coding RNAs in this condition. " 12/01/2012 - "This study was purposed to investigate the role of monocrotaline-inducing mouse liver sinusoid endothelial cell (SEC) injury in hepatic veno-occlusive disease. " 01/01/2023 - "Main methods: We established a model for MCT-induced hepatic sinusoidal obstruction syndrome, and then carried out microarray for liver tissues of SD rats in a model of early hepatic sinusoidal obstruction syndrome (12 h Monocrotaline treatment vs. control group) to investigate the differentially expressed Long non-coding RNAs and mRNAs in early hepatotoxicity. " 07/01/2021 - "Monocrotaline (MCT) administration induces liver injury in rodents that mimics the pathology of human sinusoidal obstruction syndrome. " 08/01/2019 - "To investigate the value of liver stiffness in rats with various degrees of hepatic sinusoidal obstruction syndrome (HSOS) induced by monocrotaline by comparing liver histopathologic findings. "
4.	Pyrrolizidine AlkaloidsIBA 01/01/2019 - "This study evaluated hepatic lesion volumes on contrast-enhanced computed tomography (CT) images in patients with pyrrolizidine alkaloid-induced sinusoidal obstruction syndrome (PA-SOS) and the association of lesion volume with the clinical severity and prognosis of the disease. " 09/21/2015 - "Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats." 08/11/2023 - "Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids." 07/08/2023 - "Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury, such as pyrrolizidine alkaloids, to the liver sinusoidal endothelial cells, and the gut microbiota may be involved. " 01/01/2023 - "The definitive treatment for pyrrolizidine alkaloids (PAs)-induced hepatic sinusoidal obstruction syndrome (HSOS) is not available. "
5.	Bevacizumab (Avastin)FDA Link 05/01/2009 - "Bevacizumab decreased the severity of the sinusoidal obstruction syndrome. " 01/01/2011 - "Bevacizumab: a new potential therapeutic option in sinusoidal obstruction syndrome." 05/01/2009 - "This analysis shows that bevacizumab protects against the sinusoidal obstruction syndrome and thus provides the histological explanation of the safe use of bevacizumab prior to liver resection. " 07/11/2008 - "We need to be aware that bevacizumab can cause sinusoidal obstruction syndrome (veno-occlusive disease) and that the occurrence of ascites should not be attributed to progressive disease without appropriate evaluation." 07/11/2008 - "We present the case of a patient with colon cancer who, while receiving bevacizumab, developed sinusoidal obstruction syndrome (veno-occlusive disease) (SOSVOD). "
6.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/09/2023 - "Although cyclophosphamide in high doses may cause sinusoidal obstruction syndrome, hepatocellular liver injury is rare. " 04/01/2006 - "In specific patients, cyclophosphamide can be associated with hepatic veno-occlusive disease at immunosuppressive doses." 04/01/2006 - "To report on a patient developing hepatic veno-occlusive disease while being treated with immunosuppressive doses of cyclophosphamide (< or =2 mg/kg). " 11/01/2020 - "Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide." 02/20/1999 - "This observation offers three original types of information: there has been no prior report of an association between veno-occlusive disease and POEMS syndrome, the role of low dose cyclophosphamide in hepatic veno-occlusive disease was certain, transjugular intrahepatic portosystemic shunt is an interesting therapy with one years remission."
7.	Busulfan (Busulfex)FDA Link 10/01/2023 - "However, simply controlling the exposure of Busulfan may not effectively prevent or reduce the occurrence of hepatic sinusoidal obstruction syndrome. " 01/01/2018 - "Patients 1, 2, and 3 required increases in remaining daily busulfan doses to achieve AUC targets, and no adjustment was required in patient 4. Patient 5's AUC was 49.7% higher than expected, and he subsequently developed fatal sinusoidal obstruction syndrome. " 08/01/2012 - "Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant." 06/01/2011 - "A high busulfan area under the plasma concentration curve (>1500 μM·min) is associated with an increased risk for sinusoidal obstruction syndrome, and a suboptimal area under the plasma concentration curve (<900 μM·min) is associated with an increased risk for graft rejection or disease relapse. " 08/01/2009 - "The most common significant toxicity of busulfan is sinusoidal obstruction syndrome. "
8.	Alprostadil (Muse)FDA LinkGeneric 10/01/1988 - "[The treatment with prostaglandin E1 of a suspected hepatic veno-occlusive disease in a leukemic patient]." 09/01/1994 - "[A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation]." 01/01/1991 - "Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1." 10/01/2000 - "Low dose heparin and lipo prostaglandin E1 were used in prophylactic regimen for hepatic veno-occlusive disease. " 01/01/1998 - "Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin."
9.	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 10/01/2008 - "Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen." 02/01/2016 - "Thiotepa-related toxicity was mainly digestive, whereas sinusoidal obstruction syndrome was the main toxicity observed after Bu-Mel. " 02/01/2017 - "Our data suggest that thiotepa-based conditioning therapy in AML is feasible, effective and safe, as investigated for sinusoidal obstruction syndrome and mucositis." 01/01/2018 - "For patients with sinusoidal obstruction syndrome, conditioning included either busulfan (Bu)/Cy (n = 5), Cy with total body irradiation (n = 4), or thiotepa (n = 2). " 10/01/2008 - "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. "
10.	beraprostIBA 09/01/2020 - "Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome." 09/01/2020 - "In this study, the liver sinusoidal endothelial cells (LSECs)-protective effects of beraprost sodium (BPS) were investigated using mice with monocrotaline (MCT)-induced sinusoidal obstruction syndrome (SOS). "

Therapies and Procedures

1.	Hematopoietic Stem Cell Transplantation 10/01/2023 - "The aim of this study was to evaluate the concordance between clinical diagnosis and pathologic findings of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in post-hematopoietic stem cell transplantation recipients and to investigate the accuracy of the HOKUS-10 score in diagnosing VOD/SOS. " 01/01/2020 - "The aim of this study is to evaluate the incidence of sinusoidal obstruction syndrome (SOS) of the liver and the clinical outcome after hematopoietic stem cell transplantation (HSCT) based on several modifications in our protocols. " 10/01/2006 - "Studies investigating the effect of prophylactic drugs on hepatic veno-occlusive disease (VOD) development are rare in children that have undergone allogeneic hematopoietic stem cell transplantation (HSCT). " 05/01/2002 - "Reports of clinical research studies on the natural history and laboratory correlates of central nervous system, pulmonary, and hepatic dysfunction (generally manifesting as the syndrome of hepatic veno-occlusive disease) during hematopoietic stem cell transplantation. " 10/01/2000 - "Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study."
2.	Stem Cell Transplantation 02/01/2010 - "The occurrence of hepatic veno-occlusive disease (VOD) has been reported in up to 60% of patients following stem cell transplantation (SCT), with incidence varying widely between studies depending on the type of transplant, conditioning regimen, and criteria used to make the diagnosis. " 08/01/2007 - "We initially conducted a multicenter, randomized trial (n=43), and subsequently a questionnaire study (n=209) of participating hospitals, to evaluate whether infused fresh frozen plasma (FFP) could prevent the occurrence of hepatic veno-occlusive disease (VOD) after stem cell transplantation (SCT). " 10/01/2023 - "Concordance between HokUS-10 Scoring and Transjugular Liver Biopsy for the Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Allogeneic Stem Cell Transplantation." 05/01/2023 - "Sinusoidal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatening complication of haematopoietic stem-cell transplantation (HSCT). " 01/01/2023 - "Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is an established complication in patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT). "
3.	Cell Transplantation 01/01/2020 - "The remission rate of InO is about 75%; however, the frequency of sinusoidal obstruction syndrome is increased when allogeneic hematopoietic cell transplantation is performed after InO treatment. " 02/01/2023 - "Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a rare, serious complication following haematopoietic cell transplantation (HCT). " 02/01/2023 - "A systematic literature review of the clinical signs and symptoms of veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation in adults and children." 01/01/2023 - "Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). " 01/01/2023 - "BACKGROUNDCurrently, no laboratory tests exist to stratify for the risk of developing sinusoidal obstruction syndrome (SOS), an early endothelial complication after hematopoietic cell transplantation (HCT). "
4.	Drug Therapy (Chemotherapy) 11/01/2017 - "We chose to study hepatic parenchymal heterogeneity on the basis of the assumption that hepatic parenchymal heterogeneity may indicate the presence of chemotherapy-induced sinusoidal obstruction syndrome (SOS). " 01/01/2023 - "Sinusoidal obstruction syndrome (SOS) of the liver is a complication of chemotherapy most often encountered with hematopoietic stem cell transplant due to high-dose conditioning regimens, but it can also occur with regimens outside of the transplant setting. " 01/01/2022 - "Hepatic sinusoidal obstruction syndrome post-chemotherapy in pediatric and adolescent age: case series of six patients in Qatar." 01/01/2021 - "Of note, hepatic sinusoidal obstruction syndrome (HSOS) induced by OXA has become a key concern for patients with CRC receiving chemotherapy with OXA in recent years. " 01/01/2021 - "Sinusoidal obstruction syndrome (SOS) is a life-threatening liver complication of high- dose chemotherapy. "
5.	Therapeutics 01/01/2022 - "6-TG maintenance therapy in children with ALL can enhance the overall effective rate, can reduce the first remission mortality and the total recurrence rate, and will not increase the overall incidence of adverse reactions, but the incidence of reversible or irreversible hepatic veno-occlusive disease is remarkably increased, which has a certain clinical value. " 01/01/2021 - "The primary endpoint was the occurrence of severe sinusoidal obstruction syndrome (SOS) or grade ≥4 pulmonary complications within the first 28 days after completion of consolidation therapy. " 01/01/2018 - "Sinusoidal obstruction syndrome in a paediatric patient with acute lymphoblastic leukaemia after completion of reinduction therapy according to ALL Intercontinental Berlin-Frankfurt-Münster 2009." 02/01/2017 - "Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies." 01/01/2006 - "Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome."